In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 141 to 150 of 294

TitleTypeExpected publication date
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]Technology appraisal guidanceTBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]Technology appraisal guidanceTBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Technology appraisal guidanceTBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]Technology appraisal guidanceTBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]Technology appraisal guidanceTBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237]Technology appraisal guidance
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]Technology appraisal guidance
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All